CHEMOMAB THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.839 USD | +3.58% |
|
+13.38% | +64.51% |
| May. 06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
| Apr. 10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11.92M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-14
x | P/E ratio 2025 * |
-18.6
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Chemomab Therapeutics Ltd.
More recommendations
More press releases
| 1 day | +3.58% | ||
| 1 week | +13.38% | ||
| Current month | +19.86% | ||
| 1 month | +10.39% | ||
| 3 months | +39.83% | ||
| 6 months | +42.20% | ||
| Current year | +64.51% |
1 week
0.60
0.97
1 month
0.580.97
Current year
0.460.97
1 year
0.421.89
3 years
0.4227.92
5 years
0.4279.00
10 years
0.4279.00
| Managers | Title | Age | Since |
|---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 11-09-21 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 19-12-31 |
| Chief Tech/Sci/R&D Officer | 56 | 22-11-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 20-03-31 |
Nissim Darvish
CHM | Chairman | 59 | 21-03-15 |
Claude Nicaise
BRD | Director/Board Member | 71 | 21-03-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.839 | +3.58% | 69,651 |
| 24-05-09 | 0.81 | +11.72% | 124,859 |
| 24-05-08 | 0.725 | -18.42% | 426,854 |
| 24-05-07 | 0.8887 | +4.21% | 404,239 |
| 24-05-06 | 0.8528 | +15.24% | 1,262,762 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.839
USD
Average target price
6.5
USD
Spread / Average Target
+674.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +64.51% | 11.92M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- CMMB Stock
